All Good Things...

Despite its well-received genome-wide association scan papers, DeCode Genetics is on the brink of extinction, says Technology Review. According to the article, DeCode has spent more than $600 million, never made a profit, and has $3.7 million left as its stock hovers at 57 cents, down from $29 when the company first launched. Founder Kari Stefansson recently told investors that he is re-envisioning DeCode as a gene-based diagnostics company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.